ARQT

About Arcutis Biotherapeutics, Inc. Common Stock (ARQT) Stock

Arcutis Biotherapeutics, Inc. Common Stock (ARQT) closed the 2026-09-17 session at $26.46, up 1.22% versus the previous close (+0.32). The stock opened at $25.95 and traded between $24.34 and $26.62 during that session. Session trading volume was 5.9M shares. The volume-weighted average price (VWAP) is $25.58.

Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.

Arcutis Biotherapeutics, Inc. Common Stock has a market capitalization of $3.33 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. ARQT is listed on the XNAS exchange. The company employs approximately 354 people. Arcutis Biotherapeutics, Inc. Common Stock is headquartered in WESTLAKE VILLAGE, CA. The recorded listing date is 2020-01-31.

On this page you can find market ARQT stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.

Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.